VANCOUVER, British Columbia--(BUSINESS WIRE)--ProtoKinetix (OTCBB:PKTX) (www.protokinetix.com) is pleased to announce the addition of entrepreneur and venture capitalist, Clarence E. Smith, to its Board of Directors. Mr. Smith brings much required, substantial financial and business experience with him as an addition to the Company’s scientific accomplishments.
Clarence is a native of West Virginia and has accumulated almost 20-million shares of ProtoKinetix as he watched the Company develop its remarkable family of AAGP™ molecules. In addition to his shareholdings, Clarence has provided a line of credit to PKTX as it moves toward the production and commercialization of AAGP™’s many applications.
ProtoKinetix’ President and CEO, Ross L. Senior, says that he is looking forward to a very profitable relationship between Clarence and ProtoKinetix.
ProtoKinetix, Inc. is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that dramatically enhance the therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component.
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.
Ross L. Senior – President and CEO